Kanabo Research Ltd. innovates and validates medical Cannabis solutions for vaporization to provide precise, consistent, and trusted Cannabis medicine solutions. Through strong leadership, deep and varied experience, patent-pending formulations, and vaporization technology, Kanabo focuses on developing new treatments for Central Nervous System (CNS) disorders through targeted formulations and clinical validation.
Based in Tel Aviv, Kanabo is a medical Cannabis R&D company that develops and clinically validates formulations of Cannabis extracts for vaporization. The formulations are developed to work with the VapePodTM vaporizer platform, which is in the final stages of certification as a medical device with the Israeli Ministry of Health. The combination of the device and the formulation is designed to deliver the company’s patent-pending formulations to treat specific ailments with precision and consistency. Initial clinical trials focus on sleep disorders, and future trails will focus on other Central Nervous System (CNS) disorders.
Why Focus on Vaporization?
There are many medical routes of administration for Cannabis, including inhalation, pills/capsules, sublingual sprays/tinctures, topical lotions or patches, and more. The bioavailability and onset times of Cannabis medicines are affected by temperature control and route of administration. For Cannabis, oral ingestion leads to roughly 10% bioavailability over many hours, where inhalation can range from 30 to 50% bioavailability of cannabinoids in a much shorter amount of time (Ohlsson, 1980).
Smoking is the conventional way to inhale Cannabis, but the many health risks associated with smoking are well known. The combustion process releases dangerous toxins and inhaling cellulosic (plant) material is damaging to the lung, heart, and body. Vaporizing is the healthier alternative for patients who want the higher bioavailability and faster onset times of inhaling Cannabis (Lanz, 2016). Vaporization occurs at lower temperatures than combustion – hot enough to extract the beneficial compounds of the plant without releasing the damaging ones (Gieringer, 2004).
Vaporizing Cannabis extracts can be even safer than vaporizing raw plant material, by both removing cellulosic and fibrous materials and concentrating the active compounds of the plant. Vaporizing Cannabis extracts maximizes therapeutic impact with a smaller, more concentrated treatment dose. However, data regarding this phenomenon is lacking and more studies need to be done.
Kanabo Research has a two-pronged approach to research and product development, focusing on developing and medically validating both formulations and delivery systems. The year one development pipeline includes five formulations that target Central Nervous System (CNS) disorders, with the first formulation targeting sleep disorders. The first two formulations are already patent-pending, and will undergo clinical validation later this year and be ready for market in 2018.
In order to speed up Kanabo’s go-to-market strategy, Kanabo identified a US-based vaporizer company and manufacturer to fill the immediate need for a high-quality, safe, and reliable vaporizer platform. Kanabo is currently in the final stages of medically validating the existing device with the Israeli Ministry of Health, and holds the sole licensing rights for medically validated device outside of the US. Long term, Kanabo has designed and continues R&D for their next generation VapePod that includes metered dosing and a mobile application to track usage and other pertinent patient data.
Short term, Kanabo aims to provide turnkey solutions to licensed Cannabis companies looking to expand their product offering to include medically validated vaporizer solutions, generate new revenue streams, and integrate the most advanced medical Cannabis technologies into their company activities. Long term, Kanabo aims to be the world leader in formulations of medical Cannabis for vaporization that transform the way we develop, create, prescribe, and use Cannabis based medicines. Kanabo Research is dedicated to innovating the medical Cannabis industry by providing a safe, reliable, and trusted solutions for medical Cannabis users.
Kanabo Research recently closed their seed round funding, and is in the process of raising Series A funding. If you are interested in learning more about investment opportunities with Kanabo Research, please complete the inquiry form and a member of our Investor Relations team will follow up with you directly.